Aktie A2AMN4 SPRING BANK PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Spring Bank Pharmaceuticals, Inc.

Aktien

A2AMN4

US8494311017

SBPH

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
F-STAR THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Spring Bank Pharmaceuticals : F-star Therapeutics Announces Approval of Clinical Trial Application for FS222
Spring Bank Pharmaceuticals : F-star Therapeutics Completes Combination with Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals : F-star Therapeutics to Present New Clinical and Mechanistic Data on its LAG-3/PD-L1 Tetravalent Bispecific Antibody, FS118, at the SITC 2020 Virtual Annual Meeting
F-STAR THERAPEUTICS, INC. : Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Registrant's Certifying Accountant, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
Spring Bank Pharmaceuticals, Inc. has Changed its Name to F-star Therapeutics, Inc
Spring Bank Pharmaceuticals : Stockholders Approve Combination with F-star Therapeutics
F-Star Therapeutics Limited completed the acquisition of Spring Bank Pharmaceuticals, Inc. in a reverse merger transaction.
Spring Bank Pharmaceuticals : Stockholders Approve Combination with F-star Therapeutics
Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics
SPRING BANK PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
Spring Bank Pharmaceuticals : Announces Special Dividend of Contingent Value Rights
Spring Bank Pharmaceuticals Announces Special Dividend of Contingent Value Rights
SPRING BANK PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
Spring Bank Pharmaceuticals : Announces Poster Presentation at the 2020 Society for Immunotherapy of Cancer Annual Meeting
Spring Bank Pharmaceuticals : Announces Poster Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Spring Bank Announces Poster Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
SPRING BANK PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2AMN4 Aktie
  4. Nachrichten Spring Bank Pharmaceuticals, Inc.
  5. Andere Sprachen